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Summary Routine notiﬁcation of Staphylococcus aureus producing the Panton-
Valentine Leucocidin toxin (PVL-SA) to the North East & Central London Health
Protection Unit, a communicable disease control unit covering a population of 2.8
million, identiﬁed 115 cases in 2009—2010, including 99 skin and soft tissue infec-
tions (SSTIs), 15 severe infections and one asymptomatic colonisation. Most cases
occurred in children and young adults, unequally distributed geographically and
socio-economically. The majority of infections were community acquired and 60%
were caused by methicillin resistant strains. Overall, 27% of cases had previous SSTIs,
and 32% had contacts with SSTIs suggestive of PVL-SA albeit these were not conﬁrmed
microbiologically. This suggests that characteristics of PVL-SA infection in cases and
their families are not recognised as such leading to delay in diagnosis and low case
ascertainment. A lack of governance around effective case management may also be
contributing to the burden of disease. Further studies are recommended to evaluate
key aspects of PVL-SA management including the effectiveness of decolonisation in
the elimination of carriage and prevention of local spread.
© 2011 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
Ltd. All rights reserved.
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Introduction
Staphylococcus aureus is a common component of
the human bacterial ﬂora found in the nose and
skin. About 20% of the population are carriers of S.
aureus [1]. The organism can be pathogenic, caus-
ing illnesses ranging from minor skin infections to
invasive infections such as septicaemia or necrotiz-
ing pneumonia [2], with fatal cases being reported
[3].
Panton-Valentine leukocidin (PVL) is a cytotoxin
expressed by some strains of S. aureus (PVL-SA) that
targets human mononuclear and polymorphonu-
clear cells [4]. While the role of PVL in disease
remains unclear [5,6], a strong epidemiological link
exists between PVL-SA and skin and soft tissue
infections (SSTIs) [7] as well as severe pneumonia
and sepsis [8,9].
PVL-SA has been reported world-wide, with
the majority being community acquired [7,10—12].
Most infections occur in healthy young individuals
with no apparent risk factor for hospital acquisition
[8,9]. Identiﬁed risk factors include playing contact
sports, contact with animals, using gyms, saunas
and pools, and being in the military [13].
It has been difﬁcult to establish the true
prevalence of PVL-SA as samples received by labo-
ratories are highly selected and not representative
of the whole spectrum of disease. Further, the
majority of PVL-SA may be treated empirically
and hence not conﬁrmed microbiologically [14].
National reference laboratories in Europe report
variable prevalence for PVL-SA [7,11,12,14]. In
2002, 1.6% of all S. aureus referred to the Staphy-
lococcal Reference Unit (SRU) in England were
PVL-positive, while 24% of S. aureus recovered from
SSTIs were PVL-positive [11]. A London-based study
conducted in 2006—2007 reported a rate of 20.8%
among SSTIs [10]. Reference laboratories in the
Netherlands [14], France [7] and Belgium [15] have
reported prevalences of 15%, 37% and 39%, respec-
tively.
The North East and Central London Health
Protection Unit (NECL-HPU) is a communicable dis-
ease control unit covering a population of 2.8
million across North and East London. It pro-
vides ‘‘specialist support to prevent and reduce
the impact of infectious diseases, chemical and
radiation hazards, and major emergencies’’ [16].
NECL-HPU is routinely notiﬁed of cases of PVL-SA,
most commonly by the national SRU, but also by
clinicians or local microbiology laboratories. These
notiﬁcations prompt a risk assessment of cases, plus
a screening and decolonisation regime of cases and
close contacts in accordance with national guidance
[17].
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The aim of this study was to describe the epi-
emiology of PVL-SA cases notiﬁed to NECL-HPU
ver a one year period (May 2009—April 2010),
ncluding demographics, infection characteristics
nd case management, via a cross-sectional anal-
sis. The potential implications of the ﬁndings are
lso discussed.
ethods
esign
his retrospective cross-sectional study included
ll laboratory conﬁrmed cases of PVL-SA reported
o NECL-HPU between May 1st 2009 and April
0th 2010, extracted from the NECL-HPU propri-
tary databases. As the national SRU systematically
eports all microbiologically conﬁrmed cases to the
nit, this caseload represents all cases identiﬁed in
he speciﬁed geographical area during the deﬁned
ime period. The data were anonymised using a
nique reference number for each case, linking to
he HPU’s proprietary databases.
ase deﬁnition
conﬁrmed case was deﬁned as a case where the
VL genes were identiﬁed in a S. aureus isolate
eferred to the national SRU.
A colonisation case was deﬁned as a case where
VL-SA was identiﬁed from a screening swab (e.g.
ose, throat and/or perineum), either as part of
ontact tracing or as part as hospital screening, and
here the patient was asymptomatic.
An SSTI case was deﬁned as any localised infec-
ion of the skin or soft tissue (abscesses, boils,
nfected wounds, cellulitis) without any systemic
nvolvement.
A severe case was deﬁned as any case (including
STIs) with systemic involvement.
Hospitalisation was deﬁned as at least an
vernight stay, and did not include Accident and
mergency attendance. When duration of stay was
ot available, a minimum duration of one night
as assumed. Therefore estimations about average
ength of stay and total number of hospital bed days
re likely to be underestimated.
A hospital-acquired case was deﬁned as a case
f PVL-SA microbiologically or epidemiologically
inked to a case who was a hospital inpatient (in
he case of hospital outbreaks), or a case who was
creened MRSA negative on admission and subse-
uently developed a PVL-SA infection.
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Decolonisation organised as per policy was
eﬁned as the conﬁrmation that local decolonisa-
ion protocols, based on national guidance, were
ent to the patient’s GP (or hospital where appro-
riate), with the oral or written agreement by the
P to carry out the protocol. Decolonisation con-
isted of ﬁve days of chlorhexidine 4% or triclosan
—2% applied to the body and hair and application
f topical mupirocin to the nares for ﬁve days [17].
Feedback from GP was deﬁned as cases where
he patient’s GP contacted NECL-HPU regarding a
VL case, for any reason.
linical data collection
earch queries identifying all PVL-SA cases were run
n the two HPU databases used during the study
eriod.
A Microsoft Excel database was designed,
apturing geographical and demographic informa-
ion, source of reporting, timeframes, methicillin
usceptibility (including mecA status), type of
nfection, origin of infection, treatment and
anagement, risk factors, risk assessment and
anagement of screening and decolonisation.
able 1 describes the recorded dataset.
While some of the information (demograph-
cs, source of report and timelines) was directly
mported from the NECL-HPU databases, the rest
f the information was extracted from standardised
uestionnaires routinely submitted for each PVL-SA
ase. These questionnaires are completed by either
PU staff, GPs or hospital staff, and then scanned to
he database. Each questionnaire was downloaded
nd analysed. When information was not in the
atabase, paper archives were consulted, includ-
ng laboratory reports and patient questionnaires.
nswers were recorded as ‘‘unknown’’ when there
as no clear indication of the information being
ecorded explicitly.
tatistical analysis
escriptive statistics were used to summarise the
haracteristics of cases included in the cohort.esults
15 cases of PVL-SA were identiﬁed between May
009 and April 2010.
i
(
w
oigure 1 Age distribution of PVL-SA cases, by gender.
emographics
verall, 70/115 (61%) were male, 45/115 (39%)
ere female. The burden of disease fell mainly on
oung children and adults of working age (Fig. 1),
elatively sparing young adults and the elderly. The
ge distribution was even more unequal in the 15
ases of severe disease, with under 5 s represent-
ng 40% (n = 6) of cases; 20% (n = 3) and 33% (n = 5)
ases occurred in the 5—15 and 25—49 age groups,
espectively.
Geographical distribution also demonstrated
ide variations. Three boroughs (City and Hackney,
arnet and Camden) represented 27.7% of the cov-
red population but accounted for 50% of the cases.
ig. 2 maps every case across the covered area, and
hows microbiology laboratories serving the area.
Socio-economic stratiﬁcation, based on the
fﬁce for National Statistics socio-economic clas-
iﬁcation 2010 [18], is shown in Table 2.
easonal trends
ata were plotted by week and by month but no
easonal trends could be established.
ype of infection
ost patients (99; 86.1%) presented with SSTIs; 15
13%) had severe disease with systemic involve-
ent, including one death. Severe cases were
iagnosed with septicaemia (n = 10), pneumonia
n = 3), osteomyelitis or septic arthritis (n = 4), liver
bscess (n = 1) and neutropenia (n = 1); more than
ne diagnosis was recorded for some cases. One
ndividual was colonised with PVL-SA. Most cases
99; 86.1%) were community acquired; 14 (12.2%)
ere hospital acquired and for 2 cases (1.7%), the
rigin was unclear.
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Table 1 Conﬁrmed PVL-SA cases: clinical and demographic data.
Topic Details Number of cases (total n = 115)
Age Mean = 26.8 years Median = 29
years
Mode = <1 year
(n = 15)
Sex Male (n = 70) Female
(n = 45)
Demographics Postcode n/a
Occupation n/a
Methicillin susceptibility MRSA/MSSA MRSA (n = 69) MSSA (n = 46)
Type of infection Colonization/
SSTI/severe
Colonisation only
(n = 1)
SSTI (n = 99) Severe (n = 15)
Details of
infection
n/a
Origin Hospital
acquired/community
acquired
HA = 14 CA = 99 Unknown= 2
Treatment Hospitalised? Yes (n = 68) No (n = 43) Unknown
(n = 4)
Length of
hospital stay
Mean 8.8 days
(range 1—67
days)
I&D performed? Yes (n = 52) No (n = 56) Unknown
(n = 7)
Antibiotic used? Yes (n = 92) No (n = 18) Unknown
(n = 5)
Type of antibiotic n/a
Risk assessment Previous lesions? Yes (n = 31) No (n = 62) Unknown
(n = 22)
Skin condition? Yes (n = 31) No (n = 62) Unknown
(n = 22)
HH contact with
lesions in past
year?
Yes (n = 37) No (n = 61) Unknown
(n = 17)
Anyone in
workplace/school
with a similar
infection
n = 2
Use of
gym/sauna/pool
n = 9
Contact sports? n = 3
Animal contact? n = 7
Child (<16) n = 28
Immunocompromised n = 3
Health care
worker or carer
n = 5
At nursery,
college or
university
n = 1
Diabetic or has
other injected
medication
n = 7
In the military n = 0
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Table 1 (Continued)
Topic Details Number of cases (total n = 115)
Contact risk factors Child (<16) n = 46
Immunocompromised n = 1
Skin condition n = 10
Health care
worker or carer
n = 3
At nursery,
college or
university
n = 6
Diabetic or has
other injected
medication
n = 1
In the military n = 0
Decolonisation Organised as per
policy?
Yes (n = 102) No (n = 13)
Feedback from
GP?
Yes (n = 25) No (n = 90)
VL-
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6Figure 2 Geographical distribution of P
The reported cases included a cluster of 6 cases
n a neonatal intensive care unit. One case was in a
ealthcare worker, ﬁve were in neonates. The time-
ine suggests the healthcare worker may have been
he index case, having had a thigh abscess caused
y PVL-SA not initially reported to the HPU.ethicillin susceptibility
verall, 69 (60%) PVL-SA were methicillin resistant
MRSA, mecA positive), while 46 (40%) were methi-
m
d
u
cSA cases across North and East London.
illin sensitive (MSSA, mecA negative). The majority
f severe infections (10 of 15; 67%) were methicillin
ensitive.
ase management
8 cases (61.3%) required hospitalisation, with a
ean length of stay of 8.8 days and a median of 4
ays (range 1—67 days). This ﬁgure is likely to be an
nderestimate (see ‘‘case deﬁnition’’ section). 52
ases (42.5%) required an incision and drainage, and
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Table 2 Socio-economic status of 69 microbiologically conﬁrmed PVL-SA adult cases.
Socio economic category Number of cases %Total
Higher managerial/higher administrative 1 1.4
Higher professional 2 2.9
Lower professional/higher technical 7 10.1
Lower managerial/lower administrative 3 4.3
Intermediate occupation 6 8.7
Employer in small organisation 1 1.4
Semi-routine occupation 4 5.8
Routine occupation 5 7.2
Long term unemployed 11 15.9
Retired 7 10.1
Student 2 2.9
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92 (80%) were prescribed antibiotics. Notably, 36%
of prescriptions for MRSA cases were inappropriate
(-lactam antibiotics).
Decolonisation was organised as per national
guidance in 102 cases (88.7%). Of the 13 cases
where decolonisation was not organised, 10 were
due to inability to contact the case. The remaining
3 were attributable to miscommunication surround-
ing the decolonisation protocol between the GP and
NECL-HPU.
While protocols were forwarded to GPs in almost
90% of cases, feedback from GPs was obtained
in only 19 instances (16.5%). Reasons for GP calls
included request for case management advice
(n = 7), request for information about case (n = 5),
informing NECL-HPU that decolonisation had been
carried out (n = 3), providing NECL-HPU with new
information (n = 2) and notifying of non-reception
of decolonisation protocol (n = 2). In all cases there
was no microbiological follow up to conﬁrm suc-
cessful eradication.
Risk factors
Risk factor data are shown in Fig. 3. Skin lesions
in the 12 months prior to current diagnosis were
reported in 31 (27%) cases, while 37 (37.2%) had
household contacts who had been symptomatic in
the previous year. 15 (13.2%) cases had an under-
lying skin condition. Details were not available for
15—21% cases.
Symptomatic household contacts of cases had a
variety of symptoms: 34/37 (92%) had boils and/or
abscesses, 2/37 (5.5%) were found to be colonised
and 1/37 (2.5%) had another (unspeciﬁed) form of
skin infection. 15/37 (40%) households with symp-
tomatic contacts had more than one symptomatic
individual in the household. Only one case with
p
P
f
P20 29
evere infection had symptomatic household con-
acts.
Risk factors previously associated with PVL-SA
uch as using a gym (n = 9), animal contact (n = 7)
nd contact sports (n = 3) were identiﬁed (Table 1).
o further case ﬁnding was undertaken in gym users
r contact sport players.
iscussion
he scope of the present study is broader than many
revious publications. The study reinforces some
idely recognised aspects of PVL-SA epidemiology,
ighlights some little studied facts and raises some
ew questions.
emographics and infection characteristics
he demographic data are concordant with those
f previous studies: PVL-SA tends to be community-
cquired [20,21], affect healthy young individuals
8,9,12,19] with males predominating [10]. There
as no strong preponderance of either MSSA or
RSA, supporting most of the available evidence
11,12,22,23]. The majority (86.1%) of individuals
resented with SSTIs, and 13% were associated with
ore severe disease [7,11], ﬁgures consistent with
he published literature.
Socio-economic stratiﬁcation revealed inequal-
ties and increased likelihood of PVL-SA in lower
ocio-economic groups. While the two highest
ocio-economic categories accounted for 4.3% of
he caseload, the two lowest categories and the
nemployed comprised 28.9% of cases. The use of
rivate healthcare may affect these proportions.
rivate laboratories may have different thresholds
or forwarding isolates of S. aureus to the SRU for
VL testing.
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The unequal geographical distribution of cases
ould not be associated with any identiﬁable
emographic factors such as age, ethnicity or
eprivation and is most likely attributable to differ-
nces in referral criteria. Private discussions with
ocal microbiology laboratories highlighted the fact
hat sample referral for PVL-testing was decided
n a case-by-case basis, based on the opinion
f the microbiology specialist, or sometimes the
linician.
ase management and risk factors
he high percentage of hospital admissions (61.3%)
nd surgical procedures (42.5%) highlights the mor-
idity and burden of disease attributable to PVL-SA.
VL-related infections were responsible for a min-
mum of 587 hospital bed days in the given time
eriod. The annual cost associated with PVL-SA for
he target population (including hospital stays and
rocedures but excluding antimicrobials) exceeded
300,000. This is a conservative estimate, based on
he NHS national tariff 2010—2011 [24].
This study highlights PVL-SA infections are likely
o be underestimated and case management is
nconsistent. Although this study cannot demon-
trate any microbiological link between conﬁrmed
ases and previous skin lesions, familial transmis-
o
t
b
dtors in cases of PVL-SA.
ion of S. aureus, including PVL-SA is commonly
eported [25,26] and, looking at the high proportion
f cases with previous skin lesions and/or rela-
ives with skin lesions, epidemiologically it is likely
hat a proportion of these previous lesions were
aused by PVL-SA, but never tested. This is fur-
her illustrated by the neonatal cluster, where a
ack of management of the index case (a healthcare
orker) may have led to onward transmission to 5
eonates, some associated with severe disease and
rolonged hospital stay. It is likely that improve-
ents in case ascertainment and management
llied to improvements in control measures would
ead to a reduction in incidence and recurrence
ate.
This lack of a consistent framework for manag-
ng PVL-SA is further illustrated by the therapeutic
egimen. Out of 129 antibiotic courses pre-
cribed in the cases studied, 32 (24.8%) were
or antibiotics not listed in any of the cur-
ent recommended guidelines [27]. Additionally,
ver a third (33/91) of antibiotic courses pre-
cribed for patients with PVL-MRSA infections
ere inappropriately prescribed -lactam antibi-
tics. This is, however, mitigated by the fact
hat a large proportion of prescriptions would
e empirical and precede any microbiological
iagnosis.
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Based on this study it is not possible to assess
whether case management was effective as the
outcomes of screening and were not monitored rou-
tinely. The HPU performs a risk assessment around
each case and their close contacts. A recommenda-
tion is then made to the GP regarding the necessity
for screening and/or decolonisation of the case and
close contacts with the onus on GPs to carry it
out. There is no routine feedback mechanism to
ascertain whether this is implemented according to
recommendations, leading to the inability to build
evidence around the effectiveness of the current
decolonisation protocol.
The study sample is likely to be an underesti-
mate of the burden of disease as most patients
with SSTIs in the community are treated empiri-
cally never receive a microbiological diagnosis. The
main limitation of this study is the lack of a control
group: NECL-HPU is not notiﬁed of negative ﬁndings
from samples sent to microbiology departments
or the national SRU, preventing the estimation of
PVL negative S. aureus samples and the statistical
signiﬁcance of identiﬁed demographic and clinical
risk factors. Because of a lack of feedback follow-
ing the communication of decolonisation protocols,
adherence to and effectiveness of screening and
decolonisation protocols is beyond the scope of this
study.
Conclusion
PVL-SA is a signiﬁcant public health problem.
More effective case recognition, management,
and contact tracing along with monitoring adher-
ence to decolonisation strategies could reduce
both the burden of disease and associated cost.
This is reliant on agreed guidelines regard-
ing which cases should be tested for PVL-SA
together with building evidence and gover-
nance around treatment protocols in addition
to screening and decolonisation strategies. Fur-
ther research is needed to understand (i) the
principles of risk assessment to identify reser-
voirs or sources of infection and vulnerable
contacts, (ii) practical problems encountered
with implementing screening and decolonisa-
tion protocols and (iii) to evaluate the efﬁ-
cacy of decolonisation including pre- and post-
decolonisation screening and long term follow-up
with respect to recurrence of disease or future re-
colonisation.
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